Cargando…

Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies

HIV-1 envelope glycoproteins (Env) are the only viral antigens present on the virus surface and serve as the key targets for virus-neutralizing antibodies. However, HIV-1 deploys multiple strategies to shield the vulnerable sites on its Env from neutralizing antibodies. The V1V2 domain located at th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Guomiao, Upadhyay, Chitra, Zhang, Jing, Pan, Ruimin, Zolla-Pazner, Susan, Kong, Xiang-Peng, Hioe, Catarina E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619609/ https://www.ncbi.nlm.nih.gov/pubmed/26491873 http://dx.doi.org/10.1371/journal.pone.0141233

Ejemplares similares

Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
por: Hioe, Catarina E., et al.
Publicado: (2018)

Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes
por: Upadhyay, Chitra, et al.
Publicado: (2020)

Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations
por: Upadhyay, Chitra, et al.
Publicado: (2018)

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
por: Hioe, Catarina E., et al.
Publicado: (2010)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials
por: Balasubramanian, Preetha, et al.
Publicado: (2018)

Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity
por: Mayr, Luzia M., et al.
Publicado: (2017)

Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2
por: Mayr, Luzia M., et al.
Publicado: (2013)

Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity
por: Zolla-Pazner, Susan, et al.
Publicado: (2015)

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
por: Zolla-Pazner, Susan, et al.
Publicado: (2019)

HIV-1 Envelope Glycan Composition as a Key Determinant of Efficient Virus Transmission via DC-SIGN and Resistance to Inhibitory Lectins
por: Jan, Muzafar, et al.
Publicado: (2019)

Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing
por: Zolla-Pazner, Susan, et al.
Publicado: (2006)

P19-21. Sequence variability in the crown of the V3 loop of the HIV-1 envelope is clustered within a small 3D structural zone
por: Almond, D, et al.
Publicado: (2009)

Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins
por: Jan, Muzafar, et al.
Publicado: (2018)

Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals
por: Klingler, Jéromine, et al.
Publicado: (2021)

Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals
por: Klingler, Jéromine, et al.
Publicado: (2021)

Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth
por: Smith, S. Abigail, et al.
Publicado: (2016)

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice
por: Hioe, Catarina E., et al.
Publicado: (2022)

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120
por: Doran, Rachel C., et al.
Publicado: (2014)

Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity
por: Lai, Jennifer I., et al.
Publicado: (2020)

Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
por: Schulz, Sebastian R., et al.
Publicado: (2022)

Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
por: Almond, David, et al.
Publicado: (2012)

Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies
por: Carbonetti, Sara, et al.
Publicado: (2014)

Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses
por: Manhas, S, et al.
Publicado: (2012)

Stabilization of the V2 loop improves the presentation of V2 loop–associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers
por: de Taeye, Steven W., et al.
Publicado: (2019)

A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
por: Weiss, Svenja, et al.
Publicado: (2020)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques
por: Devasundaram, Santhi, et al.
Publicado: (2020)

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers
por: Bontjer, Ilja, et al.
Publicado: (2013)

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies
por: Wang, Haoqing, et al.
Publicado: (2017)

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein
por: Tian, Jianhui, et al.
Publicado: (2016)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
por: Swetnam, J, et al.
Publicado: (2009)

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020)

The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time
por: Fox, Alisa, et al.
Publicado: (2022)

Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies
por: Kuriakose Gift, Syna, et al.
Publicado: (2023)

Rational optimization of a human neutralizing antibody of SARS-CoV-2
por: Chen, Jiao, et al.
Publicado: (2021)

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1
por: Morgand, Marion, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l8t9a98r57eqg9g1u4pdv79her